About 140 million Americans, more than half of the nation's adults, could be considered candidates for weight loss drugs ...

There's been pressure put on Novo Nordisk to lower the cost of Ozempic and Wegovy. In late September, company CEO Lars ...

More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Analysts look at the likelihood of lawmakers making moves to rein in drug middlemen this session. Also, covid-era prescription flexibility is kept in place, pharmaceutical companies take on GLP-1 ...

In general, when a person prepares for a surgery, the guidance is to fast before going under anesthesia–but for patients, on GLP-1’s there may still be ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Weight loss drugs are incredibly sought-after, but they’re also often difficult to obtain due to limited insurance coverage ...

Lifecore now operates at less than 35% utilization, meaning that it can almost triple revenue with virtually no additional ...

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

Eli Lilly and Co.’s recent decision to drop development at phase II of PD-1 agonist peresolimab in rheumatoid arthritis (RA) because of an inadequate benefit-risk profile brought further attention to ...